Factors Influencing the Rate of Clinical Deterioration in Parkinson’s Disease
A Multi-Factorial Review
DOI:
https://doi.org/10.58445/rars.1254Keywords:
Parkinson's, Genetics, Environmental Factors, Covid-19Abstract
Parkinson's disease is one of the most prominent and devastating neurodegenerative disorders worldwide. However, each PD patient has a unique disease course due to individual variations in the rate of cognitive and psychomotor decline. In this review article, we will analyze factors influencing such individual variation and the amount of concrete information we currently have on PD. We will focus particularly on genetic factors, social/socioeconomic factors, and medical comorbidities using existing data and information gathered from previous experiments. We will discuss the implications such factors should have on treatment options and disease management and the effects the COVID-19 pandemic had on PD patients.
References
Statistics | Parkinson’s Foundation. Accessed November 12, 2023. https://www.parkinson.org/understanding-parkinsons/statistics
Sonne J, Reddy V, Beato MR. Neuroanatomy, Substantia Nigra. In: StatPearls. StatPearls Publishing; 2023. Accessed October 1, 2023. http://www.ncbi.nlm.nih.gov/books/NBK536995/
Australia H. Dopamine. Published November 6, 2023. Accessed November 12, 2023. https://www.healthdirect.gov.au/dopamine
Funayama M, Nishioka K, Li Y, Hattori N. Molecular genetics of Parkinson’s disease: Contributions and global trends. J Hum Genet. 2023;68(3):125-130. doi:10.1038/s10038-022-01058-5
Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson’s disease: Genetics and Cognition in PD. Mov Disord. 2012;27(4):512-518. doi:10.1002/mds.24946
Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease. J Neurol. 2009;256(3):493-498. doi:10.1007/s00415-009-0119-8
Hoehn and Yahr Scale. Physiopedia. Accessed November 12, 2023. https://www.physio-pedia.com/Hoehn_and_Yahr_Scale
Ball N, Teo WP, Chandra S, Chapman J. Parkinson’s Disease and the Environment. Front Neurol. 2019;10. Accessed October 1, 2023. https://www.frontiersin.org/articles/10.3389/fneur.2019.00218
Langston JW. The MPTP Story. J Park Dis. 2017;7(s1):S11-S19. doi:10.3233/JPD-179006
MAO-B Inhibitors | Parkinson’s Foundation. Accessed October 1, 2023. https://www.parkinson.org/living-with-parkinsons/treatment/prescription-medications/mao-b-inhibitors
Pyatha S, Kim H, Lee D, Kim K. Association between Heavy Metal Exposure and Parkinson’s Disease: A Review of the Mechanisms Related to Oxidative Stress. Antioxidants. 2022;11(12):2467. doi:10.3390/antiox11122467
Cheng P, Yu J, Huang W, et al. Dietary intake of iron, zinc, copper, and risk of Parkinson’s disease: a meta-analysis. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2015;36(12):2269-2275. doi:10.1007/s10072-015-2349-0
Meamar R, Nikyar H, Dehghani L, Basiri K, Ghazvini MRA. Assessing of plasma levels of iron, zinc and copper in Iranian Parkinson’s disease. Adv Biomed Res. 2016;5(1):31. doi:10.4103/2277-9175.178788
Costa-Mallen P, Gatenby C, Friend S, et al. Brain Iron Concentrations in Regions of Interest and Relation with Serum Iron Levels in Parkinson Disease. J Neurol Sci. 2017;378:38-44. doi:10.1016/j.jns.2017.04.035
Contributors WE. What Is Oxidative Stress? WebMD. Accessed October 21, 2023. https://www.webmd.com/a-to-z-guides/what-is-oxidative-stress
Weiss Annulation - an overview | ScienceDirect Topics. Accessed October 1, 2023. https://www.sciencedirect.com/topics/chemistry/weiss-annulation
Protein Aggregation - an overview | ScienceDirect Topics. Accessed October 1, 2023. https://www.sciencedirect.com/topics/neuroscience/protein-aggregation
Brooks SK, Weston D, Greenberg N. Social and psychological impact of the COVID-19 pandemic on people with Parkinson’s disease: a scoping review. Public Health. 2021;199:77-86. doi:10.1016/j.puhe.2021.08.014
Exercise | Parkinson’s Foundation. Accessed February 18, 2024. https://www.parkinson.org/living-with-parkinsons/treatment/exercise
Shalash A, Roushdy T, Essam M, et al. Mental Health, Physical Activity, and Quality of Life in Parkinson’s Disease During COVID ‐19 Pandemic. Mov Disord. 2020;35. doi:10.1002/mds.28134
How Stress and Stress Management Impact Parkinson’s | Parkinson’s Foundation. Published November 16, 2021. Accessed January 28, 2024. https://www.parkinson.org/blog/how-stress-and-stress-management-impact-parkinsons
Feeney MP, Xu Y, Surface M, et al. The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study. Npj Park Dis. 2021;7(1):10. doi:10.1038/s41531-020-00153-8
Bulkes NZ, Davis K, Kay B, Riemann BC. Comparing efficacy of telehealth to in-person mental health care in intensive-treatment-seeking adults. J Psychiatr Res. 2022;145:347-352. doi:10.1016/j.jpsychires.2021.11.003
Fearon C, Fasano A. Parkinson’s Disease and the COVID-19 Pandemic. J Park Dis. 2021;11(2):431-444. doi:10.3233/JPD-202320
Fasano A, Cereda E, Barichella M, et al. COVID-19 in Parkinson’s Disease Patients Living in Lombardy, Italy. Mov Disord Off J Mov Disord Soc. 2020;35(7):1089-1093. doi:10.1002/mds.28176
Artusi CA, Romagnolo A, Imbalzano G, et al. COVID-19 in Parkinson’s disease: Report on prevalence and outcome. Parkinsonism Relat Disord. 2020;80:7-9. doi:10.1016/j.parkreldis.2020.09.008
McMaughan DJ, Oloruntoba O, Smith ML. Socioeconomic Status and Access to Healthcare: Interrelated Drivers for Healthy Aging. Front Public Health. 2020;8:231. doi:10.3389/fpubh.2020.00231
Okoro CA, Strine TW, Young SL, Balluz LS, Mokdad AH. Access to health care among older adults and receipt of preventive services. Results from the Behavioral Risk Factor Surveillance System, 2002. Prev Med. 2005;40(3):337-343. doi:10.1016/j.ypmed.2004.06.009
NIMH » What is Prevalence? Accessed November 11, 2023. https://www.nimh.nih.gov/health/statistics/what-is-prevalence
Lix LM, Hobson DE, Azimaee M, Leslie WD, Burchill C, Hobson S. Socioeconomic variations in the prevalence and incidence of Parkinson’s disease: a population-based analysis. J Epidemiol Community Health. 2010;64(4):335-340. doi:10.1136/jech.2008.084954
Schapira AHV. Parkinson’s disease. BMJ. 1999;318(7179):311-314.
Parkinson’s Disease – Symptoms, Diagnosis and Treatment. Accessed October 1, 2023. https://www.aans.org/
Pedrosa DJ, Timmermann. Review: management of Parkinson's disease. Neuropsychiatr Dis Treat. Published online March 2013:321. doi:10.2147/NDT.S32302
Levodopa and the Progression of Parkinson’s Disease. N Engl J Med. 2004;351(24):2498-2508. doi:10.1056/NEJMoa033447
Mak MK, Wong-Yu IS, Shen X, Chung CL. Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat Rev Neurol. 2017;13(11):689-703. doi:10.1038/nrneurol.2017.128
Rahimpour S, Gaztanaga W, Yadav AP, et al. Freezing of Gait in Parkinson’s Disease: Invasive and Noninvasive Neuromodulation. Neuromodulation J Int Neuromodulation Soc. 2021;24(5):829-842. doi:10.1111/ner.13347
Downloads
Posted
Categories
License
Copyright (c) 2024 Sarah Wang
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.